Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer
Neoadjuvant chemotherapy (NAT) is increasingly used for the treatment of non‐metastatic pancreatic ductal adenocarcinoma (PDAC) and is established as a standard of care for borderline resectable and locally advanced PDAC. However, full exploitation of its clinical benefits is limited by the lack of...
Saved in:
| Main Authors: | Manoj Amrutkar, Sander Johannes Thorbjørnsen Guttorm, Anette Vefferstad Finstadsveen, Knut Jørgen Labori, Lars Eide, Helge Rootwelt, Katja Benedikte Prestø Elgstøen, Ivar P. Gladhaug, Caroline S. Verbeke |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13759 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FOLFIRINOX for advanced pancreatic adenocarcinoma in Brazil: a single-institution experience
by: José Mauricio Mota, et al.
Published: (2018-01-01) -
[Comment] Brazil-TNT : a randomized phase 2 trial of neoadjuvant chemoradiation followed by FOLFIRINOX versus chemoradiation for stage Ⅱ/Ⅲ rectal cancer
by: Li Laiyuan, et al.
Published: (2024-08-01) -
Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
by: Adam R. Wolfe, et al.
Published: (2020-07-01) -
Administration of FOLFIRINOX for Advanced Pancreatic Cancer: Physician Practice Patterns During Early Use
by: Joanna Gotfrit, et al.
Published: (2025-02-01) -
A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX
by: Shuhei Yamada, et al.
Published: (2023-08-01)